PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING
JL Palmer, VC Munk, R Kotchie, G Vincze, Charney k, D Tucker, L AnnemansVolume:
11
Year:
2008
Language:
english
DOI:
10.1016/s1098-3015(10)70622-7
File:
PDF, 75 KB
english, 2008